Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H27NO |
| Molecular Weight | 321.4559 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=PHTMLLGDZBZXMW-AERCQKQUSA-N
InChI=1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21+
| Molecular Formula | C22H27NO |
| Molecular Weight | 321.4559 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ethybenzatropine (Ponalid) is an anticholinergic and antihistaminergic drug. It was used as an antiparkinsonian agent. A significant increase in the duration of action of levodopa-induced improvement in parkinsonian symptoms was observed following the administration of ethybenzatropine. Ethybenzatropine also improved, or tended to improve the duration and seventy of onset and end-of-dose levodopa-induced dyskinesias. Thus when levodopa is administered together with etybenzatropine, its length of action on parkinsonian symptoms is prolonged.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2779590
Nine patients with Parkinson’s disease: Levodopa was given orally
together with a peripheral DOPA-decarboxylase inhibitor at the usual effective morning dosage for each patient. The same dose of levodopa was administered the next day in addition to ethybenzatropine, 5 mg given i.v. Ethybenzatropine was administered between 0 and 15 min after the first dose of levodopa
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:10 GMT 2025
by
admin
on
Mon Mar 31 18:22:10 GMT 2025
|
| Record UNII |
G1X2X9N95N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN04AC30
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
||
|
WHO-ATC |
N04AC30
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
||
|
NCI_THESAURUS |
C66880
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
G1X2X9N95N
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
524-83-4
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
1358000
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
G1X2X9N95N
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
m5080
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB07348MIG
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
C65562
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
DB13468
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
DTXSID50905096
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
1247
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104273
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
4423
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
100000082136
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
Etybenzatropine
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY | |||
|
C027641
Created by
admin on Mon Mar 31 18:22:10 GMT 2025 , Edited by admin on Mon Mar 31 18:22:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |